Spero Therapeutics, Inc. — Director's Dealing 2017

Nov 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2017-11-06

Reporting Person: Sendek Joel (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-06	Common Stock	C	10181	—	Acquired	10181	Indirect
2017-11-06	Common Stock	P	5000	$14.00	Acquired	15181	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-06	Series C Preferred Stock	$	C	61880	Disposed		Common Stock (10181)	Indirect

Footnotes

F1: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date.

F2: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.